PeptideStack
5.2kquestions
20kanswers
220users

How does tirzepatide at 15 mg weekly compare on cost per milligram across routes?

Asked 30 Oct 2025Modified 7 months agoViewed 7.4k times
17

The particulars: tirzepatide · 15 mg.

I would like the arithmetic checked rather than the conclusion asserted.

I have deliberately not used an online calculator because I want to be able to check the result.

Can someone show the working rather than just the answer?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
IB
askedilaria_bertone33k3830 Oct 2025

5 Answers

Sorted by votes
47

15 mg a week is 780 mg a year and 65 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 780 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

Answer first: compare cost per milligram of measured peptide, not per milligram of label claim, because content varies enough to reverse a comparison.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
VR
answeredv_ramaswamy68k5723 Dec 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
32

The relevant arithmetic is that a fifteen per cent price advantage disappears against a ten per cent content shortfall plus a testing cost.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Independent testing prices at the services this community uses are published and are stable enough to model.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
BU
answeredbufferline4230k13812 Dec 2025
7Small correction: carriage amortises across the order, which changes small-order economics entirely. – Dr_Rosalind_Achebe 3 months ago
8The point about the code being on the glass rather than the box is worth its own thread. – aine_mulcahy 5 months ago
add a comment
23

Answering this needs the order size, because carriage and testing amortise very differently across one vial and across ten.

Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

The relevant detail is that dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Carriage on international consignments scales sub-linearly with weight, which is the quantitative basis for order consolidation.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
DV
answereddead_volume56k481 Dec 2025
4Worth flagging that comparing across laboratories is comparing laboratories, not suppliers. – kirsi_lahtinen 16 days ago
add a comment
19

Testing cost per milligram falls sharply with order size, which is the main argument against very small repeat orders.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

The caveat is that optimising cost per milligram optimises for the wrong thing if documentation and consistency are what you actually need.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
GA
answeredgrainne_ahearn50k3820 Nov 2025
18

The honest answer is that the cheapest headline price is frequently not the cheapest outcome.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
WO
answeredw_okoye43k1379 Nov 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.